715 related articles for article (PubMed ID: 27633821)
1. Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis.
Tappeiner C; Mesquida M; Adán A; Anton J; Ramanan AV; Carreno E; Mackensen F; Kotaniemi K; de Boer JH; Bou R; de Vicuña CG; Heiligenhaus A
J Rheumatol; 2016 Dec; 43(12):2183-2188. PubMed ID: 27633821
[TBL] [Abstract][Full Text] [Related]
2. Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients.
Calvo-Río V; Santos-Gómez M; Calvo I; González-Fernández MI; López-Montesinos B; Mesquida M; Adán A; Hernández MV; Maíz O; Atanes A; Bravo B; Modesto C; Díaz-Cordovés G; Palmou-Fontana N; Loricera J; González-Vela MC; Demetrio-Pablo R; Hernández JL; González-Gay MA; Blanco R
Arthritis Rheumatol; 2017 Mar; 69(3):668-675. PubMed ID: 27696756
[TBL] [Abstract][Full Text] [Related]
3. Tocilizumab for refractory uveitis associated with juvenile idiopathic arthritis: A report of two cases.
Dipasquale V; Atteritano M; Fresta J; Castagna I; Conti G
J Clin Pharm Ther; 2019 Jun; 44(3):482-485. PubMed ID: 30815892
[TBL] [Abstract][Full Text] [Related]
4. Abatacept in the treatment of severe, longstanding, and refractory uveitis associated with juvenile idiopathic arthritis.
Tappeiner C; Miserocchi E; Bodaghi B; Kotaniemi K; Mackensen F; Gerloni V; Quartier P; Lutz T; Heiligenhaus A
J Rheumatol; 2015 Apr; 42(4):706-11. PubMed ID: 25641892
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis.
Marino A; Marelli L; Nucci P; Caporali R; Miserocchi E
Ocul Immunol Inflamm; 2023 Dec; 31(10):1997-2000. PubMed ID: 36657742
[TBL] [Abstract][Full Text] [Related]
6. Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients.
Vegas-Revenga N; Calvo-Río V; Mesquida M; Adán A; Hernández MV; Beltrán E; Valls Pascual E; Díaz-Valle D; Díaz-Cordovés G; Hernandez-Garfella M; Martínez-Costa L; Calvo I; Atanes A; Linares LF; Modesto C; González-Vela C; Demetrio-Pablo R; Aurrecoechea E; Cordero M; Domínguez-Casas LC; Atienza-Mateo B; Martín-Varillas JL; Loricera J; Palmou-Fontana N; Hernández JL; González-Gay MA; Blanco R
Am J Ophthalmol; 2019 Apr; 200():85-94. PubMed ID: 30660771
[TBL] [Abstract][Full Text] [Related]
7. Comparable Efficacy of Abatacept Used as First-line or Second-line Biological Agent for Severe Juvenile Idiopathic Arthritis-related Uveitis.
Birolo C; Zannin ME; Arsenyeva S; Cimaz R; Miserocchi E; Dubko M; Deslandre CJ; Falcini F; Alessio M; La Torre F; Denisova E; Martini G; Nikishina I; Zulian F
J Rheumatol; 2016 Nov; 43(11):2068-2073. PubMed ID: 27633826
[TBL] [Abstract][Full Text] [Related]
8. Impact of Antiinflammatory Treatment on the Onset of Uveitis in Juvenile Idiopathic Arthritis: Longitudinal Analysis From a Nationwide Pediatric Rheumatology Database.
Tappeiner C; Schenck S; Niewerth M; Heiligenhaus A; Minden K; Klotsche J
Arthritis Care Res (Hoboken); 2016 Jan; 68(1):46-54. PubMed ID: 26212111
[TBL] [Abstract][Full Text] [Related]
9. Tocilizumab treatment for refractory uveitis-related cystoid macular edema.
Adán A; Mesquida M; Llorenç V; Espinosa G; Molins B; Hernández MV; Pelegrín L
Graefes Arch Clin Exp Ophthalmol; 2013 Nov; 251(11):2627-32. PubMed ID: 23893042
[TBL] [Abstract][Full Text] [Related]
10. Juvenile idiopathic arthritis-associated uveitis.
Sen ES; Ramanan AV
Best Pract Res Clin Rheumatol; 2017 Aug; 31(4):517-534. PubMed ID: 29773271
[TBL] [Abstract][Full Text] [Related]
11. Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet's disease: multicentre retrospective study.
Atienza-Mateo B; Calvo-Río V; Beltrán E; Martínez-Costa L; Valls-Pascual E; Hernández-Garfella M; Atanes A; Cordero-Coma M; Miquel Nolla J; Carrasco-Cubero C; Loricera J; González-Vela MC; Vegas-Revenga N; Fernández-Díaz C; Demetrio-Pablo R; Domínguez-Casas LC; Luis Martín-Varillas J; Palmou-Fontana N; Hernández JL; González-Gay MÁ; Blanco R
Rheumatology (Oxford); 2018 May; 57(5):856-864. PubMed ID: 29471416
[TBL] [Abstract][Full Text] [Related]
12. Patient satisfaction and clinical effectiveness of switching from intravenous tocilizumab to subcutaneous tocilizumab in patients with juvenile idiopathic arthritis: an observational study.
Ayaz NA; Karadağ ŞG; Koç R; Demirkan FG; Çakmak F; Sönmez HE
Rheumatol Int; 2020 Jul; 40(7):1111-1116. PubMed ID: 32417938
[TBL] [Abstract][Full Text] [Related]
13. A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial).
Ramanan AV; Dick AD; Benton D; Compeyrot-Lacassagne S; Dawoud D; Hardwick B; Hickey H; Hughes D; Jones A; Woo P; Edelsten C; Beresford MW;
Trials; 2014 Jan; 15():14. PubMed ID: 24405833
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis.
Kostik MM; Dubko MF; Masalova VV; Snegireva LS; Kornishina TL; Chikova IA; Isupova EA; Kuchinskaya EM; Glebova NI; Buchinskaya NV; Kalashnikova OV; Chasnyk VG
Pediatr Rheumatol Online J; 2015; 13():4. PubMed ID: 25685108
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous Tocilizumab for Cystoid Macular Edema Secondary to Juvenile Idiopathic Arthritis (JIA)-associated Uveitis: A Case Report.
Adán A; Moll-Udina A; Ramirez J; Llorenç V
Ocul Immunol Inflamm; 2021 Jan; 29(1):6-8. PubMed ID: 31589540
[No Abstract] [Full Text] [Related]
16. Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis.
García-De-Vicuña C; Díaz-Llopis M; Salom D; Bou R; Díaz-Cascajosa J; Cordero-Coma M; Ortega G; Ortego-Centeno N; Suarez-De-Figueroa M; Cruz-Martínez J; Fonollosa A; Blanco R; García-Aparicio ÁM; Benítez-Del-Castillo JM; Antón J
Mediators Inflamm; 2013; 2013():560632. PubMed ID: 24489444
[TBL] [Abstract][Full Text] [Related]
17. TWENTY-FOUR MONTH FOLLOW-UP OF TOCILIZUMAB THERAPY FOR REFRACTORY UVEITIS-RELATED MACULAR EDEMA.
Mesquida M; Molins B; Llorenç V; Hernández MV; Espinosa G; Sainz de la Maza M; Adán A
Retina; 2018 Jul; 38(7):1361-1370. PubMed ID: 28520640
[TBL] [Abstract][Full Text] [Related]
18. Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis?
Tappeiner C; Heinz C; Ganser G; Heiligenhaus A
J Rheumatol; 2012 Jun; 39(6):1294-5. PubMed ID: 22661419
[No Abstract] [Full Text] [Related]
19. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan.
Yokota S; Imagawa T; Mori M; Miyamae T; Takei S; Iwata N; Umebayashi H; Murata T; Miyoshi M; Tomiita M; Nishimoto N; Kishimoto T
J Rheumatol; 2014 Apr; 41(4):759-67. PubMed ID: 24634205
[TBL] [Abstract][Full Text] [Related]
20. Leflunomide is associated with a higher flare rate compared to methotrexate in the treatment of chronic uveitis in juvenile idiopathic arthritis.
Bichler J; Benseler SM; Krumrey-Langkammerer M; Haas JP; Hügle B
Scand J Rheumatol; 2015; 44(4):280-3. PubMed ID: 25993023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
